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Supplementary Figure 1: Workflow of the project 
 
Overview of the analysis workflow for trans-ethnic (a), European ancestry-specific (b), and 
diabetes-specific (c) genome-wide association meta-analyses (GWAMA). The Venn diagram in 
panel (d) shows the number of overlapping loci between the different GWAMA. 
 
Supplementary Figure 2: Regional association plots for loci identified in trans-ethnic GWAS 
meta-analysis of UACR 
  



























































Regional association plots are shown for all genome-wide significant index SNPs. The dots are 
plotted on the y-axis according to their meta-analysis association p-value, and colored according 
to their correlation r² with the index SNP estimated based on the 1000 Genomes EUR reference 
samples (gray for missing data). Plots were generated using the stand-alone version 1.3 of 
LocusZoom2. Genetic positions refer to GRCh37/hg19 coordinates. 
  
Supplementary Figure 3: Expected number of discoveries at increasing GWAS discovery sample 
sizes. 
 
 
The panels show the estimate the number of expected discoveries (a) and the corresponding 
percentage of GWAS heritability explained (b) with increases in sample size using the summary 
statistics of our UACR trans-ethnic meta-analysis as input. The vertical blue line marks the 
number of predicted discoveries for UACR at the current sample size and may represent an 
underestimate because of many SNPs with small effects.  
Supplementary Figure 4: Regional association plots for loci identified in trans-ethnic GWAS 
meta-analysis of UACR among individuals with diabetes 
  








Regional association plots are shown for all genome-wide significant index SNPs. The dots are 
plotted on the y-axis according to their meta-analysis association p-value, and colored according 
to their correlation r² with the index SNP estimated based on the 1000 Genomes EUR reference 
samples (gray for missing data). Plots were generated using the stand-alone version 1.3 of 
LocusZoom2. Genetic positions refer to GRCh37/hg19 coordinates.  
Supplementary Figure 5: Manhattan plots for all secondary GWAS meta-analyses 
 
 
Manhattan plots of the GWAS meta-analysis results for UACR in individuals of European ancestry 
(a), in individuals of African ancestry (b), and among trans-ethnic individuals with diabetes (c). 
SNPs are plotted on the x-axis according to their position on each chromosome with the  
-log10(p-value) of the meta-analysis association test on the y-axis. The solid horizontal line 
indicates the threshold for genome-wide significance, 5x10-8. The labels show the closest gene. 
New loci are colored in blue, previously published UACR loci in orange. Genomic loci in panel (c) 
that are specific for individuals with diabetes are marked with an asterisk. 
 
  
Supplementary Figure 6: QQ plots plots for all GWAS meta-analyses 
 
 
Quantile-quantile (QQ) plots of the GWAS meta-analysis results for UACR in the trans-ethnic 
sample (a), in individuals of European ancestry (b), in individuals of African ancestry (c), among 
trans-ethnic individuals with diabetes (d), and for trans-ethnic microalbuminuria meta-analysis 
(e). The observed p-values of the meta-analysis association test are plotted on the y-axis against 
their expected distribution under the null hypothesis of no association on the x-axis. Results for 
all SNPs are shown in black, and results after removal of loci (±500kb of index SNP) genome-wide 
significantly (p<5x10-8) associated with the trait are shown in yellow (the African ancestry GWAS 
revealed no genome-wide significant associations). Gray bands represent 95% confidence 
intervals. λ: lambda, genomic control parameter; n: sample size. 
  
Supplementary Figure 7: Enrichment analysis results for physiological system where UACR-
associated genes are highly expressed 
 
Results for enrichment of physiological systems based on the trans-ethnic UACR GWAS meta-
analysis obtained by DEPICT software are shown. The x-axis is labeled by MeSH first level terms. 
Nominally significant associations (p<0.05) are labeled in the figure. The y-axis represents the  
-log10(p-value) of the enrichment test implemented in DEPICT. 
  
Supplementary Figure 8: Co-localization of UACR-association signals with gene expression in cis 
across 47 human tissues 
 
  
  
 
The plot shows genes whose expression levels in any tested tissues co-localized with the UACR 
association signal with a posterior probability of ≥80%. Genes and their respective index SNP are 
shown on the y-axis. Co-localization across tissues (x-axis) is illustrated as dots, where the size of 
the dots indicates the posterior probability of the co-localization. The change in UACR is color-
coded relative to the change in gene expression, or gray in case of a posterior probability <0.80. 
Kidney tissues are labeled in bold. 
  
Supplementary Figure 9: The Drosophila OAF and PRKCI are both required for nephrocyte 
function and PRKCI-RNAi affects slit diaphragm formation 
(a) Garland cell nephrocytes were exposed to FITC-albumin. Nephrocytes expressing control-
RNAi exhibit intense endocytosis of FITC-albumin. Expression of Vrp1-RNAi has no significant 
effect on FITC-albumin uptake. (b) Quantitation of fluorescence intensity from FITC-albumin 
uptake is shown for the indicated genotypes. Values are presented as mean±standard deviation 
of the ratio to a control experiment. Statistical significance was calculated using ANOVA and 
Dunnett’s post hoc analysis. A statistically significant difference (defined as p<0.05) was not 
observed (N=4 for Vrp1-RNAi-1, N=3 for Vrp1-RNAi-2). 
(c) Staining the slit diaphragm proteins Sns (ortholog of nephrin) and Kirre (ortholog of NEPH1) in 
nephrocytes expressing oaf-RNAi-2 shows regular formation of slit diaphragms on the entire 
nephrocyte surface. (d) Tangential sections through the surface of control nephrocytes reveals 
the regular fingerprint-like pattern of slit diaphragm proteins. 
(e-f) Expression of aPKC-RNAi-2 results in an clustered and irregular pattern of slit diaphragm 
proteins (inset in e) and a complete loss of slit diaphragm protein from distinct areas on the cell 
surface (insets f). 
3D reconstructions from sequential confocal sections of nephrocytes expressing (g) control-RNAi 
and (h) aPKC-RNAi are shown. The surface is completely covered but slit diaphragm protein in 
the control but upon silencing aPKC large gaps appear. 
(i-k) Staining control garland cell nephrocytes using anti-aPKC ζ, an antibody that is known to 
detect Drosophila aPKC, reveals a punctate staining pattern that is concentrated at the periphery 
of the cell including the membrane (i). Expression of aPKC-RNAi-1 (j) and aPKC-RNAi-2 (k) results 
in a distinct reduction of the antibody signal from the cell surface and periphery. This indicates a 
successful knockdown of aPKC on the protein level. Images were recorded at identical settings of 
the confocal microscope. 
All scale bars represent 10 µm. 
  
Supplementary Table 1: Association results of the UACR genetic risk score quartiles with 
microalbuminuria in the UKBB 
Quartile Effect SE Odds ratio (95% CI) P-value N cases N controls 
I reference 6,281 54,096 
II 0.159 0.019 1.17 (1.13-1.22) 2.24E-17 7,001 51,618 
III 0.282 0.018 1.33 (1.28-1.38) 7.45E-53 7,583 49,799 
IV 0.527 0.018 1.69 (1.64-1.75) 3.04E-191 9,149 47,224 
 
Supplementary Table 2: Association results of the genetic risk score (GRS) analyses of UACR 
and it’s risk factors 
Exposure Outcome 
N 
SNPs Effect SE 
OR 
(95% CI) P-value N cases N total Interpretation of effect 
UACR CAD 57 0.003 0.085 1.00 
(0.85-1.18) 
0.975 60,801 184,305 change in log(OR) of CAD per 
SD unit increase of log(UACR) 
UACR HF 59 0.398 0.158 1.49 
(1.09-2.03) 
0.012 6,065 408,313 change in log(OR) of HF per 
SD unit increase of log(UACR) 
UACR HTN 59 0.386 0.041 1.47 
(1.36-1.59) 
2.38E-21 226,011 408,539 change in log(OR) of HTN per 
SD unit increase of log(UACR) 
UACR Stroke 57 0.145 0.074 1.16 
(1.00-1.34) 
0.049 67,162 521,612 change in log(OR) of Stroke per 
SD unit increase of log(UACR) 
DBP UACR 319 0.007 0.001 - 1.23E-24 - 757,601 change of SD unit of log(UACR) 
per mm Hg DBP increase 
SBP UACR 244 0.008 0.001 - 3.52E-63 - 757,601 change of SD unit of log(UACR) 
per mm Hg SBP increase 
T2DM UACR 138 0.018 0.003 - 1.01E-10 62,892 659,316 change of SD unit of log(UACR) 
per unit increase in T2DM GRS 
N SNPs gives the number of SNPs included in the genetic risk score. Significant P-values are marked bold. 
N cases: number of cases; N total: total sample size of the non-UACR trait; OR [95% CI]: Odds ratio with 95% 
confidence interval; SD: standard deviation 
CAD: coronary artery disease
3
 
HF: heart failure (assessed in the UK BioBank) 
HTN: hypertention (assessed in the UK BioBank) 
Stroke: any stroke
4
 
DBP, SBP: diastolic and systolic blood pressure
5
 
T2DM: type 2 diabetes
6
 
 
  
Supplementary Table 3: Evidence for additional candidate causal genes at UACR-associated 
variants 
Gene SNP credible 
set size 
variant PP functional 
consequence 
CADD DHS Brief summary of literature and gene 
function 
EDEM3 rs78444298 2 0.92 p.Pro746Ser 
(NP_079467.3) 
24.6 - The protein encoded by the ER 
Degradation Enhancing Alpha-
Mannosidase Like Protein 3 (EDEM3) 
gene belongs to a group of proteins 
that accelerate degradation of 
misfolded glycoproteins in the ER. It 
catalyzes mannose trimming of N-
glycans. This variant has been reported 
in an exome chip study of eGFR (PMID: 
27920155). 
CUBN rs45551835 1 1.00 p.Ala2914Val 
(NP_001072.2) 
34.0 - The cubilin gene (CUBN) has been 
reported in the first GWAS of UACR 
(PMID: 21355061) and has been 
replicated many times since. The 
encoded cubilin protein is important 
for reabsorption of filtered albumin in 
the proximal tubule. CUBN KO mice 
lose albumin in the urine (PMID: 
21926402). Rare mutations cause aut-
rec megaloblastic anemia-1, Finnish 
type (#261100). Patients show low-
molecular weight proteinuria (PMID: 
11717447).  
CPS1 rs1047891 15 0.96 p.Thr1412Asn 
(NP_001116105.1) 
22.1 - Carbamoyl-Phosphate Synthase 1 
(CPS1) encodes a key enzyme of the 
urea cycle that is important to remove 
excess urea. Rare mutations cause aut-
rec carbamoylphosphate synthetase I 
deficiency (#237300). GWAS locus for 
eGFR (PMID: 20383146) and many 
other quantitative biomarkers. This 
variant has been reported to associate 
with hyperammonemia after valproate 
therapy (PMID: 23997965).  
GCKR rs1260326 5 0.09 p.Leu446Pro 
(NP_001477.2) 
0.1 1* The Glucokinase Regulator (GCKR) 
gene encodes a regulatory protein 
inhibiting glucokinase in pancreatic 
islet cells and liver. Has been identified 
in previous GWAS of serum albumin 
(PMID: 23022100), glycated albumin 
(PMID: 29844224) and multiple other 
cardiometabolic traits including 
diabetes.  
This table includes all genes supported by missense variants with high posterior probability (>0.5) of association, or missense 
variants mapping into small credible sets of size ≤5. 
1*: ENCODE kidney 
 
  
Supplementary Table 4: Results of the trans-eQTL analysis 
*1: PBMC and Whole Blood, LIFE A1&B3 study
7–9
 
*2: Whole Blood, Framingham Heart Study
10
 
  
SNP meta-
analysis 
SNP 
Chr:Position 
(b37) 
SNP p-
value  
meta-
analysis  
Max. 
Posterior 
Probability  
meta-
analysis 
LD 
between 
SNP and 
eQTL-SNP 
(r
2
) 
eQTL-SNP eQTL-SNP 
Chr:Position 
(b37) 
eQTL-
Gene 
Chr 
eQTL 
Gene 
Tissue 
source 
of eQTL 
study 
p-value 
eQTL 
inter- 
chromo-
somal 
trans-
eQTL 
rs12714144 2:85754578 5.5E-14 0.194 0.97 chr2:85753464:D 2:85753464 DPEP3 16 *1 1.29E-14 yes 
rs12714144 2:85754578 5.5E-14 0.194 0.97 2:85753464:TTTG_ 2:85753464 DPEP3 16 *2 5.51E-11 yes 
rs2240060 6:31114900 6.4E-10 0.183 1 rs115017941 6:31115604 BTN3A2 6 *1 3.08E-08 no 
rs2240060 6:31114900 6.4E-10 0.183 1 6:31108485 6:31108485 BTN3A2 6 *2 2.70E-11 no 
rs2240060 6:31114900 6.4E-10 0.183 1 rs115017941 6:31115604 HLA-DRB1 6 *1 3.21E-126 no 
rs2240060 6:31114900 6.4E-10 0.183 1 6:31108485 6:31108485 HLA-DRB1 6 *2 1.82E-63 no 
Supplementary Table 5: Co-localization results of UACR association signals with those from 
associations with plasma protein levels 
PP: posterior probability; LD: linkage disequilibrium; PP H4 abf: posterior probability of the H4 test (one common causal variant of 
trait and pQTL association) 
  
UACR SNP 
UACR 
SNP 
chr 
UACR SNP 
position protein name protein SNP 
protein 
SNP 
chr 
protein 
SNP 
position 
protein SNP 
type LD (r
2
) 
No. 
SNPs PP H4 abf 
rs12790943 11 120058623 OAF.6414.8.3 rs508205 11 120057343 conditional_hit 0.90 1526 0.99 
rs1010553 3 52540773 AP4M1.10076.1.3 rs12493107 3 52706724 top_sentinel 0.50 1163 0.68 
rs162890 5 131623658 C1QTNF5.7810.20.3 rs11955347 5 131567924 top_sentinel 0.41 1398 0.62 
rs838142 19 49252151 CCL25.14068.29.3 rs35106244 19 49203829 top_sentinel 0.22 1492 0.55 
rs838142 19 49252151 ALPI.10463.23.3 rs679574 19 49206108 top_sentinel 0.23 1492 0.53 
rs12790943 11 120058623 OAF.6414.8.3 rs117554512 11 120098329 top_sentinel 0.00 1527 0.42 
rs838142 19 49252151 FUT3.4548.4.2 rs679574 19 49206108 top_sentinel 0.23 1492 0.35 
rs838142 19 49252151 FGF19.2762.30.2 rs601338 19 49206674 top_sentinel 0.24 1492 0.31 
rs838142 19 49252151 GOLM1.8983.7.3 rs601338 19 49206674 top_sentinel 0.24 1492 0.27 
rs838142 19 49252151 FAM177A1.8039.41.3 rs679574 19 49206108 top_sentinel 0.23 1492 0.26 
rs838142 19 49252151 CCL15.14109.15.3 rs681343 19 49206462 top_sentinel 0.24 1492 0.25 
rs838142 19 49252151 FAM3D.13102.1.3 rs601338 19 49206674 top_sentinel 0.24 1492 0.22 
rs6119771 20 30770375 POFUT1.5634.39.3 rs35968884 20 30818823 conditional_hit 0.00 814 0.06 
rs2240060 6 31114900 CREB3L4.11308.8.3 rs41558819 6 31324166 conditional_hit 0.00 6890 0.016 
rs2240060 6 31114900 LRPAP1.3640.14.3 rs28572463 6 31209854 conditional_hit 0.01 6890 0.002 
rs56043834 19 41331149 MIA.2687.2.1 rs2604877 19 41275048 top_sentinel 0.01 1672 0.0005 
rs1010553 3 52540773 SEMA3G.5628.21.3 rs13091025 3 52467324 conditional_hit 0.11 1162 0.0003 
rs35572189 17 79419025 ENTHD2.7947.19.3 rs61745945 17 79205421 top_sentinel 0.00 1858 0.0003 
rs2240060 6 31114900 LRPAP1.8829.4.3 6:31149622 6 31149622 conditional_hit 0.01 6890 0.0002 
rs56043834 19 41331149 MIA.2687.2.1 rs34532358 19 41288723 conditional_hit 0.08 1660 7.0E-05 
rs2240060 6 31114900 GNLY.3195.50.2 rs558163186 6 31253305 top_sentinel 0.06 6891 2.1E-05 
rs6119771 20 30770375 POFUT1.5634.39.3 rs76143353 20 30815755 top_sentinel 0.04 815 2.0E-05 
rs15052 19 41813375 B3GNT8.9297.12.3 rs557663478 19 41933790 top_sentinel 0.00 1303 1.7E-05 
rs12714144 2 85754578 GNLY.3195.50.2 rs10169536 2 85912860 conditional_hit 0.02 1503 1.6E-05 
rs15052 19 41813375 B3GNT2.7980.72.3 rs67047091 19 41938684 top_sentinel 0.00 1303 1.5E-05 
rs2240060 6 31114900 GZMA.3440.7.2 rs10569394 6 31240246 top_sentinel 0.06 6891 1.4E-05 
rs7115200 11 71752160 STAB1.14599.18.3 rs139130389 11 71850156 top_sentinel 0.00 1417 1.4E-05 
rs1010553 3 52540773 SEMA3G.5628.21.3 rs2016575 3 52477080 top_sentinel 0.06 1163 1.3E-05 
rs7115200 11 71752160 CST8.10572.65.3 rs139130389 11 71850156 top_sentinel 0.00 1417 1.2E-05 
rs2240060 6 31114900 LRPAP1.3640.14.3 rs41552714 6 31324756 top_sentinel 0.01 6891 2.1E-06 
rs2240060 6 31114900 LRPAP1.8829.4.3 rs41552714 6 31324756 top_sentinel 0.01 6891 2.1E-06 
rs2240060 6 31114900 CREB3L4.11308.8.3 rs9295987 6 31349844 top_sentinel 0.02 6891 1.6E-06 
rs2240060 6 31114900 LILRB1.5090.49.2 rs141232332 6 31075601 top_sentinel 0.14 6891 1.5E-06 
rs12790943 11 120058623 IL25.4137.57.2 rs2508490 11 120099679 top_sentinel 0.01 1527 4.1E-08 
rs12714144 2 85754578 GNLY.3195.50.2 rs17430897 2 85912962 conditional_hit 0.01 1504 2.6E-10 
rs12714144 2 85754578 GNLY.3195.50.2 rs12151621 2 85934499 top_sentinel 0.00 1505 1.3E-10 
rs3734692 6 43817791 VEGFA.14032.2.3 rs6921438 6 43925607 top_sentinel 0.00 1507 1.2E-12 
rs3734692 6 43817791 VEGFA.2597.8.3 rs6921438 6 43925607 top_sentinel 0.00 1507 1.2E-12 
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